YNL174W Antibody

What is YNL174W and why is it studied in yeast research?

YNL174W is a gene in Saccharomyces cerevisiae (baker's yeast) encoding a specific protein. This antibody targets the protein product of the YNL174W gene. Yeast serves as an excellent model organism in molecular biology due to its eukaryotic cellular organization, rapid growth, and well-characterized genome. Studying YNL174W contributes to our understanding of fundamental cellular processes that may have homologs in higher organisms including humans. The antibody enables researchers to track, quantify, and characterize this specific yeast protein in various experimental contexts .

What applications is the YNL174W antibody validated for?

The YNL174W antibody has been validated for multiple applications including:

• Western Blot (WB) - particularly with recombinant immunogen protein/peptide

• Enzyme-Linked Immunosorbent Assay (ELISA)

• General Enzyme Immunoassay (EIA)

• Other immunoassay techniques

This versatility allows researchers to employ the antibody in protein detection, quantification, and localization studies depending on their specific research questions .

What are the optimal storage conditions for YNL174W antibody?

For maximum stability and performance, YNL174W antibody should be stored at either -20°C or -80°C immediately upon receipt. It is formulated with preservatives (0.03% Proclin 300) and stabilizers (50% Glycerol, 0.01M PBS, pH 7.4) to maintain antibody integrity. It is crucial to avoid repeated freeze-thaw cycles as these can cause protein denaturation and loss of antibody activity. For short-term use, aliquoting the antibody into smaller volumes is recommended to minimize freeze-thaw cycles .

How should I validate the specificity of YNL174W antibody for my experiments?

Antibody validation is critical for ensuring experimental reproducibility. For YNL174W antibody, consider implementing these validation strategies:

• Positive control: Use the provided 200μg recombinant immunogen protein/peptide positive control to confirm detection capability.

• Genetic controls: When possible, test with wild-type yeast alongside YNL174W knockout strains.

• Pre-immune serum comparison: Compare results with the provided pre-immune serum to distinguish specific from non-specific binding.

• Orthogonal validation: Confirm protein detection using an alternative method (e.g., mass spectrometry).

Research indicates that genetic validation strategies generally provide the most reliable antibody characterization, with 57% of antibodies recommended based on genetic approaches confirmed in standardized protocols .

How does the performance of polyclonal YNL174W antibody compare to potential monoclonal or recombinant alternatives?

While the YNL174W antibody discussed is polyclonal, researchers should consider performance differences between antibody types. Comprehensive studies of hundreds of commercial antibodies indicate that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies across multiple applications. Specifically:

What approaches can mitigate batch-to-batch variation when using YNL174W polyclonal antibody?

Batch-to-batch variation is an inherent challenge with polyclonal antibodies. To minimize its impact:

• Standardize validation protocols: Implement consistent validation procedures for each new batch.

• Reference sample comparison: Maintain a reference sample from previous successful experiments to compare with new batches.

• Antibody titration: Perform titration experiments to determine optimal concentration for each batch.

• Cross-batch normalization: When analyzing quantitative data across experiments using different batches, implement normalization strategies.

• Detailed record-keeping: Document lot numbers, validation results, and experimental conditions.

Studies show that rigorous batch validation significantly improves experimental reproducibility. For critical long-term studies, consider requesting large lots of the antibody to minimize the need for batch changes .

How can I optimize the YNL174W antibody for low-abundance protein detection?

Detecting low-abundance proteins requires optimization strategies:

• Signal amplification: Implement tyramide signal amplification or polymeric detection systems.

• Enrichment techniques: Consider immunoprecipitation before Western blotting to concentrate the target protein.

• Reduced background: Optimize blocking conditions (test alternatives to standard blocking buffers).

• Extended incubation: Try longer primary antibody incubation at 4°C (overnight to 48 hours).

• Detection sensitivity: Use high-sensitivity chemiluminescent substrates or fluorescent secondary antibodies.

Each optimization approach should be systematically tested and documented. Remember that detection limits vary by application: Western blotting typically offers higher sensitivity than immunofluorescence for low-abundance proteins .

How should I address cross-reactivity concerns when using YNL174W antibody in complex yeast extract samples?

Cross-reactivity can complicate data interpretation, particularly in complex samples. Address this through:

• Specific controls: Include knockout/knockdown validation where the YNL174W gene is deleted or suppressed.

• Peptide competition assays: Pre-incubate antibody with excess immunizing peptide to block specific binding sites.

• Fractionation approaches: Simplify complex samples through subcellular fractionation or chromatographic separation.

• Orthogonal protein identification: Confirm identity of detected bands using mass spectrometry.

• Epitope mapping: Understand which regions of the target protein the antibody recognizes to predict potential cross-reactivity.

Research shows that 80-89% of antibodies can detect their target protein but may also detect unrelated proteins. Genetic validation using knockout controls provides the most definitive specificity assessment .

What is the most effective sample preparation protocol for Western blotting with YNL174W antibody?

For optimal Western blotting results with YNL174W antibody in yeast samples:

• Yeast cell lysis: Use glass bead disruption in buffer containing protease inhibitors, reducing agents, and detergents optimized for membrane proteins.

• Protein denaturation: Heat samples at 95°C for 5 minutes in Laemmli buffer with fresh DTT or β-mercaptoethanol.

• Gel parameters: Use 10-12% polyacrylamide gels for optimal separation based on the anticipated molecular weight.

• Transfer conditions: Implement semi-dry transfer at constant current (1.0 mA/cm²) for 60 minutes or wet transfer overnight at 30V/4°C.

• Blocking optimization: Test milk-based versus BSA-based blocking buffers to determine which provides lower background.

• Antibody dilution: Begin with 1:1000 dilution and adjust based on signal intensity.

This methodology has been refined based on standardized protocols established in collaboration with antibody manufacturers and may differ from manufacturer-provided protocols .

How can I integrate YNL174W antibody into multi-parameter analyses of yeast protein complexes?

For sophisticated analyses of protein complexes:

• Co-immunoprecipitation: Use YNL174W antibody to pull down protein complexes, followed by mass spectrometry to identify interaction partners.

• Proximity labeling: Combine with BioID or APEX2 approaches to identify proximal proteins in living cells.

• Multiplexed immunofluorescence: Use spectral unmixing to combine YNL174W detection with other yeast protein markers.

• Sequential immunoblotting: Implement multiple rounds of stripping and reprobing to analyze different components on the same membrane.

• Native PAGE analysis: Preserve protein complexes through non-denaturing electrophoresis followed by immunodetection.

Each approach requires specific optimization and validation steps. When analyzing complexes, consider that antibody accessibility to epitopes may be affected by protein-protein interactions .

What are the most common causes of false positive or false negative results with YNL174W antibody?

Understanding potential sources of error helps ensure accurate data interpretation:

False Positives:

• Cross-reactivity with structurally similar proteins

• Non-specific binding due to inadequate blocking or washing

• Secondary antibody binding to endogenous immunoglobulins

• Sample overloading causing non-specific bands

• Reagent contamination

False Negatives:

• Epitope masking by sample preparation conditions

• Protein degradation during extraction

• Inefficient protein transfer in Western blotting

• Antibody deterioration due to improper storage

• Insufficient antibody concentration or incubation time

Comprehensive studies indicate that approximately 43% of antibodies recommended based on orthogonal strategies and 57% of antibodies validated with genetic strategies perform as expected in standardized protocols .

How should I interpret conflicting results between YNL174W antibody detection and other protein detection methods?

When facing conflicting results:

• Methodological differences: Assess whether discrepancies might stem from different detection limits between methods.

• Protein modifications: Consider if post-translational modifications affect epitope recognition.

• Isoform specificity: Determine if alternative splicing or proteolytic processing creates variants detected differentially.

• Validation hierarchy: Prioritize results from genetic validation approaches which generally provide higher reliability.

• Systematic troubleshooting: Design experiments to specifically address the source of discrepancy.

Statistical analysis of hundreds of commercial antibodies reveals that approximately 632 of 2010 publications using antibodies for Western blotting employed reagents that did not specifically detect their target proteins, highlighting the importance of rigorous validation .

How can YNL174W antibody be incorporated into emerging single-cell analysis techniques?

Emerging applications include:

• Single-cell Western blotting: Microfluidic platforms for protein analysis at single-cell resolution.

• Mass cytometry (CyTOF): Metal-conjugated antibodies enable high-parameter analysis of individual cells.

• Imaging mass cytometry: Combines antibody detection with spatial resolution in tissue sections.

• Microfluidic immunofluorescence: Automated platforms for high-throughput single-cell imaging.

• Spatial transcriptomics integration: Correlate protein detection with gene expression patterns.

Each application requires specific antibody modifications and validation strategies. For single-cell applications, validation at low protein amounts becomes particularly critical .

What potential exists for using YNL174W antibody in therapeutic applications or diagnostic development?

While primarily a research tool, potential translational applications include:

• Diagnostic development: If YNL174W has homologs in pathogenic fungi, antibody-based detection systems might serve diagnostic purposes.

• Target validation: The antibody can help validate whether YNL174W homologs represent viable antifungal targets.

• Therapeutic antibody development: Understanding antibody-epitope interactions could inform therapeutic antibody design.

• Antibody-drug conjugates: The specificity could be leveraged for targeted delivery of antifungal compounds.

• CAR-T cell approaches: As demonstrated with other antibodies, specificity could be incorporated into cell-based therapies targeting fungal infections.

Recent research with engineered antibodies shows promising applications in redirecting universal Fabrack-CAR T cells, suggesting innovative possibilities for highly specific targeting systems .